Credit rating agency, CARE has assigned AA+ rating to Ranbaxy Laboratories’ long-term proposed Non Convertible Debentures (NCD) worth Rs 500 crore.
The company has received the said rating on the back of its dominant position in the domestic pharmaceutical market coupled with its established presence in the global market, which is further expected to strengthen, given its strong pipeline of Abbreviated New Drug Applications (ANDA), including First-to-file (FTF) applications.
Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.
